Good morning, ladies and gentlemen, and welcome to the Blade Air Mobility First Quarter 2025 Earnings Release Conference Call. At this time, all participants are in a listen-only mode. Later we will ...

IND application submission on track for Q2 2025: MBX 4291, a GLP-1/GIP co-agonist prodrug, is being developed as a once-monthly treatment for obesity. The Company expects to submit an IND application ...

One such product gaining attention in 2025 is Herpesyl, a nutritional supplement that claims to not just suppress herpes ...